Literature DB >> 10923860

Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences.

B L Hay Kraus1, D J Greenblatt, K Venkatakrishnan, M H Court.   

Abstract

1. The study aimed to ascertain the enzyme kinetic basis for breed differences in the biotransformation of propofol in dog and to identify the responsible canine cytochrome P450 (CYP) isoenzymes. 2. The NADPH-dependent formation of 4-hydroxypropofol (the rate-limiting biotransformation in dog) was assayed using hepatic microsomes from the male greyhound and beagle, and from both sexes in mixed-breed dogs (five of each). 3. Enzyme kinetic analysis revealed that whereas there were no significant differences in Km, Vmax averaged > 3-fold lower in greyhound compared with beagle (p = 0.032). Although average Vmax was > 3-fold higher in the male compared with female mixed-breed dogs, this difference did not achieve statistical significance (p = 0.095), probably because of the high variability of data from mixed-breed dogs. 4. Chloramphenicol (a specific CYP2B11 inhibitor) and diethyldithiocarbamate (a non-specific CYP2 inhibitor) inhibited propofol hydroxylation in all microsomes. Quinine (a CYP2D15 inhibitor) was also inhibitory, but only in one-half of the microsomes examined. Immuno-inhibition by anti-CYP2B1 sera resulted in > 50% reduction in metabolite formation in all dogs except mixed-breed females, which showed a 30% reduction. Differences in propofol hydroxylase activity between microsomal preparations were primarily attributed to a component that was sensitive to inhibition by chloramphenicol and anti-CYP2B1 sera. 5. The results indicate that propofol hydroxylation in dog is primarily mediated by CYP2B11 and that breed (and possibly gender) differences in propofol metabolism may result from differences in the liver content of this CYP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923860     DOI: 10.1080/004982500406417

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  17 in total

1.  Pharmacokinetics of oral terbinafine in horses and Greyhound dogs.

Authors:  M M Williams; E G Davis; B KuKanich
Journal:  J Vet Pharmacol Ther       Date:  2011-06       Impact factor: 1.786

2.  Absolute Quantitation of Drug-Metabolizing Cytochrome P450 Enzymes and Accessory Proteins in Dog Liver Microsomes Using Label-Free Standard-Free Analysis Reveals Interbreed Variability.

Authors:  Stephanie E Martinez; Jian Shi; Hao-Jie Zhu; Tania E Perez Jimenez; Zhaohui Zhu; Michael H Court
Journal:  Drug Metab Dispos       Date:  2019-08-19       Impact factor: 3.922

3.  Identification of canine cytochrome P-450s (CYPs) metabolizing the tramadol (+)-M1 and (+)-M2 metabolites to the tramadol (+)-M5 metabolite in dog liver microsomes.

Authors:  Tania E Perez Jimenez; Katrina L Mealey; Darren Schnider; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  J Vet Pharmacol Ther       Date:  2018-08-16       Impact factor: 1.786

4.  Involvement of human liver cytochrome P4502B6 in the metabolism of propofol.

Authors:  Y Oda; N Hamaoka; T Hiroi; S Imaoka; I Hase; K Tanaka; Y Funae; T Ishizaki; A Asada
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 5.  Species differences in tumour responses to cancer chemotherapy.

Authors:  Jessica Lawrence; David Cameron; David Argyle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

6.  Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs).

Authors:  Tania E Perez Jimenez; Katrina L Mealey; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  Drug Metab Dispos       Date:  2016-10-06       Impact factor: 3.922

7.  Pharmacokinetics of intravenous tramadol in dogs.

Authors:  Chantal J McMillan; Alex Livingston; Chris R Clark; Patricia M Dowling; Susan M Taylor; Tanya Duke; Rolf Terlinden
Journal:  Can J Vet Res       Date:  2008-07       Impact factor: 1.310

Review 8.  Pharmacogenetic and metabolic differences between dog breeds: their impact on canine medicine and the use of the dog as a preclinical animal model.

Authors:  Steven Fleischer; Michele Sharkey; Katrina Mealey; Elaine A Ostrander; Marilyn Martinez
Journal:  AAPS J       Date:  2008-02-15       Impact factor: 4.009

Review 9.  Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms.

Authors:  Michael H Court
Journal:  Vet Clin North Am Small Anim Pract       Date:  2013-09       Impact factor: 2.093

10.  Canine cytochrome P-450 pharmacogenetics.

Authors:  Michael H Court
Journal:  Vet Clin North Am Small Anim Pract       Date:  2013-06-13       Impact factor: 2.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.